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Smimmary Intracranial germinoma has usually been treated with radiation doses of 50 Gy or more, but it is
unclear whether such doses are actually necessary to cure this radiosensitive tumour. At our institution, the
standard radiation dose for intracranial germinoma was 60 Gy in the 1960s, but the dose has prospectively
been reduced stepwise to 40-45 Gy. In this paper. the treatment outcome was assessed in 84 patients (47 with
histologically confirmed disease and 37 diagnosed clinically in the post-computerised tomography era) enrolled
in both prospective and retrospective series. The 5 and 10 year survival rates for all 84 patients were 88% and
83% respectively, and the corresponding relapse-free survival rates were 88% and 85%. The 10-year relapse-
free survival rate was 88% for 31 patients receiving 19-47 Gy (median 42 Gy) to the primary tumour. 92%
for 28 patients receiving 48-52 Gy (median 50 Gy), and 83% for 25 patients receiving 54-62 Gy (median
60 Gy). and there was no significant difference among the three groups. In-field local recurrence only
developed in one patient who received 40 Gy over a protracted period and one patient who received 60 Gy. A
tumour size <3 cm and treatment in the post-computerised tomography era were associated with a better
prognosis according to univariate analysis, while age, sex, tumour site, treatment volume, the radiation dose to
both the primary and the spinal cord and the extent of surgical resection did not influence the prognosis. In
contrast, none of these factors had a significant influence in multivanrate analysis. In conclusion, intracranial
germinomas _ 4 cm in size can usually be cured with 40-45 Gy of radiation, thus avoiding the major adverse
effects of brain irradiation.
Intracranial germinoma is the most radiosensitive of the
pnmary intracranial neoplasms and its standard treatment is
radiation therapy. A radiation dose of 50Gy is most com-
monly given to the primary tumour, resulting in a cure rate
of 70-95% (Sung et al.. 1978; Wara et al., 1979; Lindstadt et
al., 1988; Dearnaley et at.. 1990). This dose of 50 Gy was
chosen empirically on the basis of the fact that it is usually
safe for normal brain tissue. However, there is some question
as to whether as much radiation as 50 Gy is really necessary
to cure this radiosensitive tumour, since testicular seminoma
(which is histologically identical to intracranial germinoma)
can be treated successfully with 25-35 Gy of radiation
(Thomas & Williams. 1992). This important issue has not
been addressed systematically in a clinical trial, probably
because of the relative rarity of germinoma and the fear of
increased recurrence following dose reduction.
At our hospital, the radiation dose used to treat intrac-
ranial germinoma has been prospectively reduced over the
past 20 years. A dose of 60 Gy was commonly used in the
1960s. at which time the disease was not so well understood,
but the dose was reduced to 50 Gy in the 1970s after recogni-
tion of its high radiosensitivity. After the late 1970s, some
patients were given even lower doses of 40-45 Gy as a pilot
study, and these lower doses have become standard since
1985 (except for patients with very large tumours). This
paper reports the results of our dose reduction study for
intracranial germinoma, together with the long-term outcome
in the patients previously given higher doses.
Patients and methods
Subjects
Eighty-four patients with intracranial germinoma who
received radiation therapy at our hospitals between January
1963 and December 1992 were eligible for this study. There
were 66 males and 18 females aged from 6 to 44 years. with a
median age of 15 years. The primary tumour site was the
pineal region in 30, the suprasellar/sellar region (including
the anterior part of the third ventricle) in 37, both the pineal
and suprasellar regions in nine, and the basal ganglia or
thalamus in eight. Forty-seven patients had histological
confirmation of the diagnosis, while the remaining 37
patients were diagnosed on the basis of clinical criteria
(Spiegel et al., 1976; Bloom, 1983; Shibamoto et al., 1994)
including a typical age, tumour site, typical computerised
tomography (CT) and/or magnetic resonance imaging (MRI)
findings, and a rapid response to radiation therapy. Twenty-
one of these 37 patients also had positive cerebrospinal fluid
(CSF) cytology findings in which large and round germinoma
cells were observed against a background of lymphocytes
(Shibamoto et al., 1994). Another 20 patients were treated
for suspected germinoma in the pre-CT era, but they were
not included in this analysis because of the relative uncer-
tainty of the diagnosis. One patient who died during the early
stage of radiotherapy was also excluded.
It is the policy at our institutions (and also at most other
Japanese institutions) not to biopsy every patient. Biopsy or
surgical resection was only attempted prior to radiotherapy
for tumours that were not typical germinomas or were
thought to be readily accessible surgically. When the CT
MRI findings were highly suggestive of germinoma,
15-20 Gy of irradiation was given first and follow-up imag-
ing was performed every week. When a rapid response was
observed, the clinical diagnosis of germinoma was established
and irradiation was continued. In our experience, no other
tumour of this region (including pineoblastoma) shrinks as
rapidly as a typical germinoma. Surgery was attempted
whenever the tumour did not respond rapidly. Surgery for
the tumour involved macroscopic total removal in seven
patients, subtotal removal in two and partial removal or
biopsy in 36. In two patients, the histological diagnosis was
established at the time of recurrence. In six patients, the
tumour specimens contained a teratoma component. Three of
them underwent macroscopic total removal of the tumour
and received 60 Gy, 50 Gy and 49 Gy, and the other three
underwent partial removal and all received 60 Gy. None of
these six patients has developed recurrence in 2-14 years
since therapy.
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Twenty-one of the 4 patients examined had slight to
moderate elevation of the hulman chorionic gonadotropin
(HCG) level in the serum or CSF, which suggested the
presence of syncytiotrophoblastic giant cells. In these
patients, the HCG level ranged from 4.9 to 550 mIU ml-'
(median 16) in the serum and from 8.2 to 229 mIUm-1'
(median 26) in the CSF (cf normal range <2.0m.IU ml-1).
The serum and CSF HCG levels were concordant in all 15
patients in whom both were eaid. None of them had
elevated m-fetoprotein or carcinoembryonic antigen levels. At
presentation, 12 patients had intraventricular CSF dissemina-
tion on CT/MRI and two had spinal metastasis on MRI/
myelography.
Radiation therapy
Radiation was given five times a week in all cases, with the
usual daily doses being 1.8 or 2.0Gy for the primary tumour
and 1.6 Gy for the craniospinal axis. The radiation used was
'Co gamma rays (until 1980) or X-rays from 6, 10 or
15 MeV linear accelerators. The techniques employed for
irradiation and our policy of determining the treatment
volume have been described in detail previously (Shibamoto
et al., 1988). A focal radiation field was commonly used
before 1972 and craniospinal radiation was routinely per-
formed in the late 1970s and early 1980s. Since 1985, we have
been using an individualised approach, in which patients with
CSF seeding or positive CSF cytology receive irradiation to
the cerebrospinal axis but otherwise focal radiation is given.
The treatment volume covered the primnary tumour site withi
a 2-4cm magi (encompassing the major part of the vent-
ricular system) in 27 patients, while it encompassed the whole
cerebrospinal axis in 40, the whole brain in nine and the
primary site plus the spinal axis in eight.
T'he radiation dose to the primary tumour has been
reduced over the years as described above. A few patients
exceptionally received lower doses at the earlier time. The
current standard dose is 40Gy for lesions <2.5 cm in
diameter, 45 Gy for those 2.5-4cm in diameter and 50 Gy
for larger lesions. For patients undergoing macroscopic total
removal, we use less than 40Gy. Thirty-one patients were
treated according to thins protocol. The dose used for the
prophyLaxis of spinal metastasis has also been reduced over
the years. In the 1960s, no spinal irrdiation was performed.
T'he most common dose used in the 1970s, the early 1980s
and after 1985 was 30Gy, 24Gy and 20OGy respectively. The
dose was specified at the centre of the mid-plane for parallel
opposing fields, at the intersection of central axes for multi-
ple or rotational fields and at the depth of spinal cord for
posteroanterior irradiation of the thoracwc to sacral spinal
canal.
Adjuvant therapy,
Only two patients received adjuvant chemotherapy. One
received cisplatin (total 550mg) and etoposide (2,640mg)
100,
0~ 50
because spinal metastasis was detected during focal
radiotherapy. This patient received both chemotherapy and
spinal irradiation after focal radiotherapy. Another patient
received intrathecal methotrexate (10mg) instead of spinal
irradiation because ofpositive CSF cytology. In five patients,
radiation therapy was given for tumours that recurred after
systemic chemotherapy without prior radiation. Four
patients had received two or three courses of cislatin (one
course, 20 mg m- for 5 days) and etoposide (one course,
60 Mg M-2 for 5 days) 7-12 months before radiotherapy.
Two of them developed local recurrence and two developed
CSF dissemination. The remaining patient had received cis-
platin (20 mg for 4 days) as well as four courses of vincristine
(I mg)-doxorubicin (40mg)-cyclophosphamide (500 mg)-
prednisolone (10-40mg) chemotherapy, and developed local
recurrence 1 year later.
Survival analysi
Patients were followed for up to 10-15 years, but two
patients were lost to follow-up after 5 years. The median
follow-up period was 106 months. The survival time and the
relapse-free survival tme were calculated from the start of
radiation therapy using the Kaplan-Meier method and
diffrncsbetween survival curves were examined by the
generalised Wilcoxon test. The infuence of various prognos-
tic factors was further exmndby multivariate analysis
using the Cox proportional hazard model. All statistical
analyses were carried out using a computer program
(HALBAU; Gendaisuugakusha, Kyoto, Japan).
Reisd
The overall 5, 10 and 15 year survival rates were 88%, 83%,
and 77% respectively (Figure 1), and the corresponding
relapse-fr-ee survival rates were 88%, 85% and 85%. Four
patients died without any evidence of tumour rcree. The
10 year survival and relapse-free survival rates for the 31
patients treated according to the current low-dose protocol
were 88% and 91%, repctvl, while the corresponding
figures for the other 53 patients were 79% and 83%
(P =0.16 and 0.29). Since these figures were not signifi-
cantly different, the two groups were combined for further
analyses.
The patients were divided into three groups according to
the dose to the primary tumour, i.e. a 50±2Gy group
(48.0-52.2 Gy, median 50.0 Gy), a lower dose group
(18.7-47.0 Gy, median 42.3 Gy), and a higher dose group
(54.0-62.0 Gy, median 60.0 Gy). The treatment volume in
the lower dose group, the 50 Gy group and the higher dose
group was the cerebrospinal axis in 17, 15 and eight patients
respectively, the primary tumour site in nine, five and 13
patients, the prirmary site and spinal axis in one, three and
four patients, and the whole brain in four, five and zero
patients. There were no signfcatdifferences in survival or
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Figwe 2 Survival according to the radiation dose to the primary
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relapse-free survival among these three groups (Figures 2 and
3). Even when only the patients with histological
confirmation were analysed, there was no difference in sur-
vival or relapse-free survival among the three groups (data
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not shown). Also, survival and relapse-free survival did not
vary significantly depending on the treatment volume (Figure
4) and the dose to the spinal axis (Table I).
Table I shows the relapse-free survival rates according to
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Fugue 3 Relapse-free survival according to the radiation dose to
the primary tumour. The differnc between the three dose
groups wre not signicant (P-values are given in Table I).
Fugwe 4 Relapse-free survival according to the treatment
volume. The differens between the four groups were not
sipificant (P-alues are given in Table I).
Taie I Rlase-free survival according to various potental prognostc factors
Relapse-free srvival (%)
Variabk n 5 years 10 years P-vahle
Sex
Male
Female
Age
< 15
> 16
Histology-
(+)
(-)
Site
p
S
P+S
BG/T
Site
P, BG/T
S, P+S
Size at presentation
<3 an
3 cm
Era
Pe-CT
Post-CT
Treatment vohlme
Primary site
CSA
Whole brain
Primary + SP
Dose (Gy)
18.7-47.0
48.0-52.2
54.0-62.0
Dose (Gy)
18.7-52.2
54.0-62.0
Spinal dose (Gy)
0-23.7
24.0-33.0
Tumour resecton
Total-subtotal
Other
66 90 86
18 83 83
45 88 84
39 88 88
45 90 85
39 86 86
30
37
9
8
89
83
100
100
89
83
75
100
38 91 91
46 86 82
46 95 95
38 80 74
21 76 70
63 93 93
27
40
9
8
31
28
25
87
91
78
88
88
92
83
87
91
78
70
88
92
77
59 90 90
25 83 77
50 84 84
34 94 84
9 100 100
75 87 84
0.37
0.82
0.82
0.55
0.21
0.46
0.44
0.55
0.39
0.38
0.022
0.020
0.51
0.13
0.95
0.69
0.27 J
] 0.58
0.53
0.29
0.39
0.37
P, pineal; S, suprasellar, BG/T, basal ganglia/thalanus; CT, computerised tomography;
CSA, cerebrosnal axis; SP, spinal axis.
'Histological diagnosis estabbshed before radiotherapy or not Two patients in whom the
histologcal diagnosis was established at recurrence are included in the histology (-)
group.
t
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various potential prognostic factors. Tumour size and treat-
ment era were found to be significant in univariate analysis.
However, the patient numbers were not balanced for treat-
ment era, tumour size, tumour site, treatment volume and
radiation dose. Therefore, a multivariate analysis was carried
out. Since none of the patients treated in the pre-CT era
received craniospinal irradiation, treatment volume could not
be used in the analysis. A multivariate analysis of site, size,
era and dose (variables no. 5-7 and 10 in Table I) showed
that none of them had a significant influence (the mul-
tivariate P value was 0.094 for size and 0.21 for treatment
era). The presence of CSF dissemination, positive CSF
cytology and elevation of the HCG level also had no
significant influence on the prognosis (data not shown).
Table II lists the patients who developed recurrence. Eighty
per cent of recurrences developed within 3 years and 90%
within 5 years. Eight recurrences (in patients nos. 1-8) were
seen before 1983. There were four local recurrences and six
CSF disseminations. In-field local recurrence was only seen in
two patients, who received radiation doses of 60Gy and
40 Gy. In patient no. 3, the second tumour developed within
the initial radiation field at nearly 10 years after therapy.
Both the primary and secondary tumours were histologically
confirmed to be pure germinomas. Patient no. 7 had exten-
sive intraventricular dissemination at presentation and was
unconscious with a very poor general condition. Radiation
was given to the whole brain in a palliative manner to a total
dose of 40.0 Gy, being delivered in 27 fractions over 49 days
with several short pauses. The tumour initially disappeared,
but recurred locally 7 months later and eventually killed the
patient. It should be noted that the radiation given to this
patient was not equivalent to 40 Gy with standard 1.8-2 Gy
daily fractions. In patient no. 2, it could not be determined
whether the recurrence was in-field or outside the radiation
field, since this patient was treated in the pre-CT era.
Among the 31 patients who were treated with 47 Gy or
less, 27 are alive without recurrence at 13-320 months
(median 75 months) after radiotherapy. One patient died of
intercurrent disease without recurrence at 75 months. Only
one patient developed in-field local recurrence, and the
remaining two patients developed CSF dissemination, one
within the volume treated with 34.2 and 39.6 Gy and another
out of the treatment volume (Table II). Table III lists the
patients who were treated with less than 38 Gy. All are alive
with no evidence of disease. It is noteworthy that two
patients received unusually low doses. Patient no. I was
treated in 1977 just after the installation of a CT scanner at
our hospital, and his tumour was found to have disappeared
after 14 Gy of whole-brain radiation. Because this patient
complained of severe radiation sickness, radiation to the
Table H Patients with recurrence
[Radiotherapy]
Tumour Size' Dose
No. site Diagnosis (mm) Surgery Field (Gylfr/day) Recurrence Status
1 Pit His >30 Bio Focal 56/30/39 Local at 32M 131M died of
(margin) brain necrosis
2 S His 35 Bio Focal 60/32/50 Local at lIM 14M DOD
(in-field or margin?)
3 P, LV His 40 Bio Focal 59.8/33/46 Local at 117M 139M DOD
+ SP + 30/20/32 (in-field)
4 S His 45 Bio Focal 50/29/47 Spinal met at 14M 15M DOD
(out of field)
5 P His 35 - Focal 60.2/35/56 Frontal lobe at 27M 30M DOD
(out of field)
6 S His 33 Par CSA TU:57/35/58 Spinal met at 24M 27M DOD
WB:40/26/42 (margin)b
SP:30/21/30
7 P,LV CIn 34 - WB 40/27/49 Local at 7M 12M DOD
(in-field)
8 S,LV Cyt 25 - WB TU:46.6/24/32 Spinal met at 15M 37M DOD
WB:20.5/11/15 (out of field)
9 S His 53 - CSA TU:49.5/35/54 Abdomen at 33M 139M NED
WB:30/22/32 (via shunt, out of field)
SP-.24/12-16/64
10 P,LV Cyt 22 - CSA TU:39.6/24/33 Cistern at 50M 56M DOD
CSA:23.7/15/22 (in-field)
Pit, pituitary; S, suprasellar, P, pineal; LV, lateral ventricle; His, histology; Cln, clnical diagnois; Cyt, cytology; Bio, biopsy; Par,
partial removal; SP, spinal axis; CSA, cerebrospinal axis; WB, whole brain; fr, fraction; TU, tumour site; met, metastasis; M, months;
DOD, died of the disease; NED, no evidence of disease.
'Longest diameter of the primary tumour at presentation. bOwing to the use of an inadequate spinal field.
Table m Patients receiving <38 Gy with no evidence of disease
Radiotherapy Follow-up
Tumour Size' Doseb period
No. Agelsex sile Diagnosis (mm) Sugery Field (Gy/fr/day) (months)
I 12fM P,S,LV Cyt 21,18,27 - CSA 19.5/15/23 189
2 26/F S Cyt 26 - Focal 35.8/16/24 165
3 32/M P His 23 Tot CSA 18.7/11/15 80
4 9/M S CIn 20 - CSA 35.5/25/41 70
5 12/M P His 26 Tot CSA 37.2/22/31 33
6 15/M P His 40 Tot Focal 36/20/28 14
P, pineal; S, suprasellar, LV, lateral ventricke; Cyt, cytology; His, histoklgy; Cln, clinical diagnosis; Tot, total
removal; CSA, cerebrospinal axis; fr, fraction.
'Longest diameter of the tumour at presentation. bRadiation dose to the primary tumour.US Y. SHIBAMOTO et al.
brain was ceased at 19.5 Gy and spinal radiation was com-
menced. During spinal radiation, repeat CT scaning
revealed no intracranial lesion, so the attending
radiotherapist decided not to give any further radiation to
the brain. Patient no. 3 received radiation for a suspected
germinoma, but the shrinkag of his tumour was not as
quick as that of typical germinoma, so the residual mass was
totally resected after 18.7 Gy of irradiation. The specimen
contained a few germinoma cells along with granulomatous
tissue, which is also chacfristic of germinoma (Kraichoke
et al., 1988). Since the lesion had been resected totally, no
further postoperative irradiation was given.
As a radiation sequela, brain necrosis developed in one
patient (no. 1 in Table II) who received irradiation twice as
described previously (Shibamoto et al., 1988). One patient
developed a chordoma within the irradiated volume at 5
years after therapy. The tumour was surgially removed and
she is currently doing well. The intllectual status more than
1 year after radiotherapy was evaluable in 77 patients. We
repeatedly asked the patients and their parents about their
memory function. Excluding 14 patients who had functional
defects that were probably due to the disease itself, evident
recent memory disturbance developed in 2 of the 17 patients
who had received doses of 54Gy or more and in 2 of the 20
patients who had received 50 ± 2 Gy. In contrast, none ofthe
26 patients who received doses of 47 Gy or less developed
memory disturbance. Evaluation of radiation-induced endo-
crine dysfunction was generally difficult because many
patients had such symptoms as a result of the original
disease, but anterior pituitary dysfunction developed after
radiotherapy in two patients who received 60Gy and 50 Gy,
while it was not identified in the patients receiving lower
doses.
A radiation dose of 50 Gy has been most commonly used to
treat intracranial germinoma. The risk of normal brain tissue
developing radiation necrosis after this dose is estimated to
be less than 0.5%, and thus 50 Gy is generally regarded as a
safe dose of radiation (Sheline et al., 1980). However, even if
brain necrosis does not occur, other adverse effects can
develop, such as hypothalamic-pituitary dysfunction and a
decrease in intellectual ability, including loss of recent
memory (Duffner et al., 1985). Therefore, it seems quite
important to investigate the possibility of dose reduction.
There have been a few previous reports on the successful
treatment of patients with intracranial germinoma using
doses of 45 Gy or less (Sung et al., 1978; Amendola et al.,
1984; Fields et al., 1987; Jenkin et al., 1990). However, the
numbers have been small and the follow-up period
insufficient in most reports, so that no firm conclusions could
be drawn. It is noteworthy, however, that a few patients have
been successfully treated with very low doses. The relatively
old literature reports two patients who are alive at 25 years
and 18 years after receiving 1,800 R and 2,950 R ofradiation
respectively (Simson et al., 1968; Camins & Mount, 1974).
Recently, Aydin et al. (1992) reported on a patient with
biopsy-proven germinoma who died accidentally after receiv-
ing 16 Gy of irradiation. At autopsy, no viable tumour cells
were found and the authors suggested that this disease could
possibly be cured by much lower doses than those currently
used. Also in our series, one patient who only received
19.5Gy is still recurrece free at 15 years.
On the other hand, we found in-field local recurrence mn
one patient who had a poor gnral condition and received
40Gy in 27 fractions given over 49 days. Because of the
protracted delivery of the radiation, this did not correspond
to the current practice ofdelivering 40Gy in 20-24 fractions
over 4-5 weeks. The literature also records many patients
who developed local recurrence after doses of 30-60 Gy
(Simson et al., 1968; Sung et al., 1978; Amendola et al.,
1984). Since the radiation procedure is not necessarily des-
cribed in detail, it is generally unclear from these reports
whether local recurr was due to underdosage or not.
Some patients may still develop local recurrence even after
50 Gy of irradiation and we had one patient who developed
recurrence 9 years after receiving a dose of60Gy. In a recent
review, Fuller et al. (1994) found no correlation between the
radiation dose and disease-free survival or overall survival.
Our results also indicated that the prognosis is not different
between patients receiving 40-45 Gy and 50Gy or more.
However, the toxicity of these lower doses appears to be less
than that of radiation doses > 50Gy. Therefore, it seems
reasonable for the standard radiation dose to be reduced to
40-45 Gy for germinomas klss than 4cm in diameter. The
next challenge may be to investigate the possibility of furher
dose reduction.
With regard to prophylactic craniospinal irradiation, the
optimum dose is still unclear. CSF dissemination occurred in
one of our patients who had positive cytology and intravent-
ricular dissemination at presentation and received 23.7 Gy to
the cranospinal axis. On the other hand, seven patients who
had positive CSF cytology and received 20 Gy or less to the
craniospinal axis are currently doing well 2-15 years after
therapy. Thus, we will continue to investigate whether 20 Gy
is an appropriate dose or not.
Systemic chemotherapy using cisplatin and etoposide is
presently being investigated for germinoma in some institu-
tions (Patel et al., 1992; Yoshida et al., 1993). The rationale
for performing chemotherapy is that radiation can have
adverse effects on the normal brain while chemotherapy does
not. However, it has become clear that chemotherapy is
associated with an unacceptably high recurrence rate
(Yoshida et al., 1993; Shibamoto et al., 1994) and the long-
term toxicity (particuarly on the genital organs) is still unc-
lear. Our study showed that intracranial germinoma can be
cured with lower radiation doses than have been standard,
thus eliminating the major adverse effects of radiation in
adolescents and adults. Therefore, chemotherapy (in com-
bination with even lower dose irradiation) may only be worth
consideration for children in whom 40 Gy of irradiation
might still have unfavourable effects and for recurrent cases.
Regarding the treatment volume, we are using an individ-
ualised approach. According to the rview by Brada & Rajan
(1990), the incidence of spinal seeding in intracranial ger-
minoma was 13% following brain irradiation alone. This rate
may be too low to justify the routine use of craniospinal
irradiation, but is also not negligible. We recently found that
patients with positive CSF cytology have a higher risk of
CSF dissemination (Shibamoto et al., 1994) and we give
prophylactic craniospinal irradiation to such patients as well
as those with CSF dissemination. On the other hand, we
have electively treated 11 patients without such findings with
focal irradiation since 1985 and have found no recurrence so
far in a median follow-up period of 45 months. Even if CSF
dissemination should develop following focal irradiation with
40Gy, it would be possible to give a second course of
irradiation of the craniospinal axis to 20-24 Gy and of the
site of recurrnce to 40-45 Gy (provided that recurrence is
outside the irradiated volume). Therefore, successful salvage
of CSF disemination might well be expected, with or with-
out additional chemotherapy. We recommend focal irradia-
tion with the doses described above for all patients with no
CSF dissemination and negative cytology.
The authors wish to thankc Dr M. Koishi for valuable help in
collecting data.
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